Literature DB >> 16358231

Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides.

Francesca Mallamaci1, Sebastiano Cutrupi, Patrizia Pizzini, Giovanni Tripepi, Carmine Zoccali.   

Abstract

BACKGROUND: Urotensin II (UTN) is a peptide highly conserved across species with disparate effects on the vascular system and it is currently unclear whether high plasma UTN levels play a vasculotoxic or a vasculoprotective role.
METHODS: In this study, we investigated the relationship between plasma UTN and sympathetic activity and cardiac natriuretic hormones in 191 hemodialysis (HD) patients without clinical evidence of heart failure.
RESULTS: Plasma UTN was significantly higher in patients with end-stage renal disease (ESRD) (median: 6.5 ng/mL) than in age matched healthy subjects (median: 3.1 ng/mL) (p<0.001). On univariate analysis, UTN was inversely related to heart rate (r=-0.24), dialysis treatment duration (r=-0.27), norepinephrine (r=-0.28), neuropeptide Y (NPY) (r=-0.66), brain natriuretic peptide (BNP) (r=-0.41) and atrial natriuretic peptide (ANP) (r=-0.28) (all p<0.008). Of note, in multiple regression analyses these associations maintained strength similar to that of the corresponding unadjusted correlation coefficients.
CONCLUSIONS: The inverse links between UTN and neuro-hormonal factors indicate that UTN down-regulation in the presence of high sympathetic activity and high BNP could be a counter-regulatory response aimed at mitigating cardiovascular (CV) damage or that UTN itself acts as a protective factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16358231

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  5 in total

Review 1.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

2.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

3.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

4.  Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.

Authors:  Anastasia Garoufi; Styliani Drapanioti; Antonios Marmarinos; Varvara Askiti; Andromachi J Mitsioni; Maria Mila; Georgia Grigoriadou; Dimitrios Georgakopoulos; Constantinos J Stefanidis; Dimitrios Gourgiotis
Journal:  BMC Nephrol       Date:  2017-03-31       Impact factor: 2.388

Review 5.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.